Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a ...

Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission ...

Genomics is on the brink of revolutionizing healthcare with breakthroughs that could redefine treatment and diagnosis. As ...

The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal ...

Eli Lilly and Co.’s Ebglyss (lebrikizumab) becomes the latest U.S. entrant in the increasingly competitive atopic dermatitis space, following FDA approval of the IL-13-targeting antibody, which will ...

Sen. JD Vance (R-Ohio), the Republican vice presidential candidate, is backtracking on whether President Trump would veto a ...

The safety profile of Dupixent in adolescents with moderate-to-severe asthma contributed to the FDA's decision.

Eczema has multiple treatments available, including AbbVie's Rinvoq, Pfizer's Cibinqo, Sanofi and Regeneron's Dupixent as ...

Eczema, also known as atopic dermatitis, is an inflammatory skin condition that can cause itching, rashes and dry patches.

The Food and Drug Administration (FDA) has expanded the approval of Dupixent ® (dupilumab) to include add-on maintenance treatment of adolescent patients aged 12 to 17 years with inadequately ...

Treatment with dupilumab led to significant improvements in remission in patients with bullous pemphigoid, an autoimmune blistering skin disease.

Regeneron Pharmaceuticals and Sanofi have received Food and Drug Administration approval for their treatment of an inflammatory condition that affects the sinuses and nasal passages in adolescents, ...